Developing a new nanoparticle-based treatment for non-small cell lung cancer
Official title: Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment
Funded at Pdx Pharmaceuticals, INC. · NIH-10922377 · Data updated 2026-11-12
This study is testing a new treatment called ARAC-02 for people with non-small cell lung cancer, using tiny particles to deliver a mix of medicines directly to the tumors to help the immune system fight the cancer better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pdx Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project start | September 5, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $160,652 |
| NIH project number | 1SB1CA287735-01A1 |
| Project ID | NIH-10922377 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer who have not responded adequately to existing therapies.
✕Less likely to help
Patients with other types of cancer or those who have already received extensive treatment may not benefit from this research.
What this research studies
This research focuses on creating an innovative immunotherapy called ARAC-02 for patients with non-small cell lung cancer (NSCLC). It utilizes a unique nanoparticle platform to deliver multiple therapeutic agents directly to tumors, enhancing the immune response against cancer cells. The approach combines a specific siRNA to target cancer cell death, an antibody to block immune checkpoints, and an immune stimulant to improve antigen presentation. This multi-faceted strategy aims to improve treatment outcomes for NSCLC patients who currently have limited options.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment efficacy for patients with non-small cell lung cancer.
How similar studies have gone: Previous research on nanoparticle-based immunotherapies has shown promising results, indicating potential for success with this novel approach.
Where this research is happening
-
Pdx Pharmaceuticals, INC.
Portland, United States Active
Researchers
- Principal investigator: Ngamcherdtrakul, Worapol — Pdx Pharmaceuticals, INC.
- Study coordinator: Ngamcherdtrakul, Worapol
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.